Why
invest in Meliodays?


Meliodays is reimagining uterine health by combining proven drugs and devices with established clinical pathways to develop targeted local therapeutics.

Underserved market with high unmet demand

Dysmenorrhea impacts up to 85% of women globally, with 38% reporting pain so severe that it disrupts daily life¹

Validation studies with 800 patients and 100 gynecologists confirm a treatment gap in current standards of care²

De-risked preclinical and clinical roadmap

~30 years of established Celecoxib safety and efficacy data

Approved IUD frame with a decades-long safety record

Low-barrier beachhead indication

Dysmenorrhea as the first target indication enables straightforward trial enrollment, lower cost, and reduced trial complexity

Option to get to a First-in-Human trial once safety data is available

Precedent exists on workflow and reimbursement

Identical workflow in OBGYN settings reduces adoption barriers in clinical settings

Reimbursement coverage follows the hormonal IUD precedent for heavy menstrual bleeding (HMB) as a therapeutic indication

References:
1 Schoep, M. E., et al. (2019). "The impact of menstrual symptoms on everyday life: a survey among 42,879 women." Am J Obstet Gynecol 220(6): 569.e561–569.e567

2 Meliodays Period Pain Report, 2024 (N.800 women in the US and Germany) 


DEVELOPMENT TIMELINE


HOW TO INVEST

Professional Investors

Request a deck, email us at ir@meliodays.com

Impact Investors

Participate via Capacura starting at €1,000.

Frequently Asked Questions (FAQ)